Rankings
▼
Calendar
ALKS Q2 2021 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena
ALKS
Alkermes plc
$5B
Q2 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$304M
+22.7% YoY
Gross Profit
$251M
82.5% margin
Operating Income
$4M
1.5% margin
Net Income
$2M
0.8% margin
EPS (Diluted)
$0.01
QoQ Revenue Growth
+20.8%
Cash Flow
Operating Cash Flow
$33M
Free Cash Flow
$27M
Stock-Based Comp.
$28M
Balance Sheet
Total Assets
$1.9B
Total Liabilities
$840M
Stockholders' Equity
$1.1B
Cash & Equivalents
$258M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$304M
$248M
+22.7%
Gross Profit
$251M
$202M
+23.8%
Operating Income
$4M
-$34M
+113.1%
Net Income
$2M
-$29M
+108.0%
Revenue Segments
Product
$161M
50%
Vivitrol
$88M
27%
Aristada And Aristada Initio
$72M
23%
← FY 2021
All Quarters
Q3 2021 →